Suppr超能文献

[通过对原发性不可切除横纹肌肉瘤早期及风险调整放疗提高局部肿瘤控制率:CWS 81和86研究结果]

[Improved local tumor control by early and risk-adjusted use of radiotherapy in primary non-resectable rhabdomyosarcomas: results of CWS 81 and 86 studies].

作者信息

Koscielniak E, Herbst M, Niethammer D, Treuner J

机构信息

Olgahospital, Abt. für Onkologie und Hämatologie, Universität Regensburg.

出版信息

Klin Padiatr. 1994 Jul-Aug;206(4):269-76. doi: 10.1055/s-2008-1046613.

Abstract

Since the lack of local tumor control was a major cause of therapy failure in the CWS-81 Study, the concept of the definitive local tumor control in patients with primary non-resectable RMS has been changed. In the CWS-81 Study RT was stratified according to the results of SL surgery at week 16-20 (after 2 cycles of CT), given only to patients who at this time stage had still microscopic or macroscopic tumor residuals. In the CWS-86 Study irradiation was given prior to SL surgery after one cycle of CT (7-10 weeks). The cumulative dose was stratified according to the degree of tumor volume reduction (32 Gy and 54.4 Gy) and given simultaneous to the second CT. The single dose was reduced (1.6 Gy) and given twice a day (accelerated hyperfractionation). This analysis excluded patients with parameningeal and extremity primaries since this group had special RT recommendation in both studies. 62% of patients had been irradiated in the CWS 81 Study and 70% in the CWS 86. The local tumor control improved dramatically in the CWS-86 Study in the group of patients who had been irradiated prior to SL surgery and still had macroscopic residues at the start of RT (rate of local tumor control 25% vs. 95%, p < .001). The average RT dose for this group was even lower in the CWS-86 Study (38.8 vs. 40 Gy). In the patients who were irradiated in clinical remission, no major change in local tumor control between studies was observed (CWS 81 82% vs. 75% CWS 86).(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

由于局部肿瘤未得到控制是CWS - 81研究中治疗失败的主要原因,原发性不可切除横纹肌肉瘤患者的确定性局部肿瘤控制概念已发生改变。在CWS - 81研究中,放疗根据第16 - 20周(2周期化疗后)保肢手术的结果进行分层,仅给予此时仍有镜下或肉眼可见肿瘤残留的患者。在CWS - 86研究中,放疗在1周期化疗(7 - 10周)后保肢手术前进行。累积剂量根据肿瘤体积缩小程度分层(32 Gy和54.4 Gy),并与第二次化疗同时进行。单次剂量降低(1.6 Gy),每天给予两次(加速超分割)。该分析排除了脑膜旁和肢体原发性肿瘤患者,因为这组患者在两项研究中都有特殊的放疗建议。CWS - 81研究中有62%的患者接受了放疗,CWS - 86研究中为70%。在CWS - 86研究中,保肢手术前接受放疗且放疗开始时仍有肉眼可见残留的患者组,局部肿瘤控制显著改善(局部肿瘤控制率25%对95%,p <.001)。该组患者在CWS - 86研究中的平均放疗剂量甚至更低(38.8 Gy对40 Gy)。在临床缓解期接受放疗的患者中,两项研究之间局部肿瘤控制没有重大变化(CWS 81为82%对CWS 86为75%)。(摘要截短于250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验